Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Fuji
McKesson
Queensland Health
Accenture
Merck

Generated: September 18, 2019

DrugPatentWatch Database Preview

Patent: 9,643,980

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,643,980
Title:Benzoxazepin oxazolidinone compounds and methods of use
Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: ##STR00001## or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
Inventor(s): Braun; Marie-Gabrielle (South San Francisco, CA), Hanan; Emily (Redwood City, CA), Staben; Steven T. (San Francisco, CA), Heald; Robert Andrew (Sawbridgeworth, GB), MacLeod; Calum (Harlow Essex, GB), Elliott; Richard (Harlow Essex, GB)
Assignee: Genentech, Inc. (South San Francisco, CA)
Application Number:15/200,307
Patent Claims:see list of patent claims

Details for Patent 9,643,980

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Try a Free Trial Genentech, Inc. (South San Francisco, CA) 2037-05-25 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Try a Free Trial Genentech, Inc. (South San Francisco, CA) 2037-05-25 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Try a Free Trial Genentech, Inc. (South San Francisco, CA) 2037-05-25 RX search
Genentech PERJETA pertuzumab VIAL; SINGLE-USE 125409 001 2012-06-08   Try a Free Trial Genentech, Inc. (South San Francisco, CA) 2037-05-25 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Fuji
McKinsey
Baxter
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.